Company news

Intellia Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress

November 2, 2022

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific Meeting

October 30, 2022

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2022 Earnings and Company Updates

October 26, 2022

Intellia Therapeutics to Present at October Healthcare Investor Conferences

September 25, 2022

Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

September 15, 2022

Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis

September 15, 2022

Intellia Therapeutics Announces Upcoming Investor Event to Present Interim Clinical Data from Ongoing First-in-Human Studies of NTLA-2002 and NTLA-2001 on September 16, 2022

September 7, 2022

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema

August 31, 2022

Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 Bradykinin Symposium

August 22, 2022

Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress

August 3, 2022

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2022 Earnings and Company Updates

July 26, 2022

Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose

June 23, 2022

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022

June 7, 2022

Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress

May 4, 2022

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering Conference

May 1, 2022

Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors

May 1, 2022

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2022 Earnings and Company Updates

April 27, 2022

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of Acute Myeloid Leukemia

March 8, 2022

Intellia Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for the Treatment of Acute Myeloid Leukemia

February 28, 2022

Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein

February 27, 2022

Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein

February 27, 2022

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Company Progress

February 23, 2022

Intellia Therapeutics Enters Lease Agreement to Build Manufacturing Facility for its CRISPR-based Therapies

February 22, 2022

Intellia Therapeutics Announces Two Upcoming Investor Events in February 2022

February 16, 2022

Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with Cancer

February 14, 2022

Intellia Therapeutics Announces Acquisition of Rewrite Therapeutics

February 2, 2022

Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2022

January 5, 2022

Intellia Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022

January 4, 2022

Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases

January 4, 2022

Intellia Therapeutics Appoints Derek Hicks as Chief Business Officer

December 19, 2021

Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema

December 12, 2021

Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)

November 21, 2021

Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at 2021 American Society of Hematology (ASH) Annual Meeting

November 4, 2021

Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress

November 3, 2021

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2021 Earnings and Company Updates

October 27, 2021

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis

October 20, 2021

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual Congress

October 19, 2021

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology

October 12, 2021

Intellia Therapeutics to Present New Preclinical Data Highlighting In Vivo and Ex Vivo Genome Editing Advances at 2021 European Society of Gene & Cell Therapy Annual Congress

October 11, 2021

Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema

October 5, 2021

Intellia Therapeutics to Present at Chardan’s 5th Annual Genetic Medicines Conference

September 26, 2021

Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia

September 15, 2021

Intellia Therapeutics to Present at September Healthcare Investor Conferences

August 30, 2021

Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress

August 4, 2021

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates

July 28, 2021

Intellia Therapeutics Announces Closing of $690 Million Public Offering of Common Stock

July 1, 2021

Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis

June 25, 2021

Intellia Therapeutics Names James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary

June 23, 2021

Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company

June 21, 2021

Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting

June 3, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 17 decks. Every deck is listed under its year.